Anti-tumor necrosis factor therapy for inflammatory bowel disease in the setting of immunosuppression for solid organ transplantation.
El-Nachef
Najwa
N
Terdiman
Jonathan
J
Mahadevan
Uma
U
D000328:Adult; D000368:Aged; D001688:Biological Products / Q000009:adverse effects / Q000627:therapeutic use; D005260:Female; D005500:Follow-Up Studies; D006085:Graft Survival; D006801:Humans; D007166:Immunosuppressive Agents / Q000009:adverse effects / Q000627:therapeutic use*; D015212:Inflammatory Bowel Diseases / Q000150:complications / Q000188:drug therapy* / Q000276:immunology; D016030:Kidney Transplantation / Q000276:immunology / Q000379:methods; D016031:Liver Transplantation / Q000276:immunology / Q000379:methods; D008875:Middle Aged; D016377:Organ Transplantation / Q000009:adverse effects / Q000379:methods; D018570:Risk Assessment; D012494:Sampling Studies; D014181:Transplantation Immunology / Q000502:physiology*; D016896:Treatment Outcome; D014409:Tumor Necrosis Factor-alpha / Q000008:administration & dosage / Q000037:antagonists & inhibitors*
D001688:Biological Products; D007166:Immunosuppressive Agents; D014409:Tumor Necrosis Factor-alpha